Advanced Technology for Myopia Control in Children and Young Adults
Key facts
- Who runs it
- University of Faisalabad
- Where
- Pakistan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 90 people enrolled
- Started
- 1 Jul 2025
- Ended
- 6 Jun 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Lenslet Spectacles
- Violet Excitation Filter Glasses
- Single Vision Lenses
- Record updated
- 25 June 2026
Who can take part
- Age
- 8 years to 20 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Diagnosis of axial myopia (high, moderate, or severe)
- Age between 8 and 20 years (inclusive)
- Male or female
- Willingness to wear prescribed glasses as instructed
- Willingness to attend all follow-up visits (3, 6, and 9 months)
- Written informed consent from participant or parent/guardian for minors
Who cannot take part
- Prior or concurrent myopia treatment other than study interventions
- Any ocular disease (e.g., cataract, glaucoma, retinal disorders)
- Any systemic disease affecting vision (e.g., diabetes, Marfan syndrome)
- History of any ocular surgery
- Allergic or physical intolerance to glasses materials
- Any ametropia other than axial myopia (e.g., hyperopia, astigmatism >1.50D)
- Current contact lens users
- Non-cooperative patients unwilling to comply with study procedures
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Myopia, or nearsightedness, is increasing rapidly worldwide, especially in children and young adults. This study tested two advanced treatments for slowing myopia progression with one control group: special lenslet spectacles (Stellest with highly aspherical lenslet technology) and violet excitation filter glasses (wavelength 420 nm) and Single vision lenses for controls. The study enrolled 90 participants aged 8 to 20 years from schools and universities in Faisalabad, Pakistan. Participants were randomly assigned to one of three groups: lenslet spectacles, violet filter glasses, or single vision lenses (control group). Visual acuity, contrast sensitivity, Spherical Equivalent and axial length were measured at the start and again after 3, 6, and 9 months and one follow up after cessation of treatment. The study aimed to determine whether these advanced technologies can effectively slow myopia progression compared to standard glasses, providing head-to-head evidence on emerging and established optical interventions for myopia control.
The 3 groups in the trial
- Lenslet Spectacles (HALT TechnologyTreatment being tested
Participants receive Essilor Stellest spectacle lenses featuring HALT (Highly Aspheric Lenslet Target) anf violet filter glasses technology. Lenses have 1.6mm thickness, refractive index 1.56, UV 400. Participants are instructed to wear glasses throughout all waking hours for 9 months and for VF atleast 3ours.
Treatment: Lenslet Spectacles
- Violet Excitation Filter GlassesTreatment being tested
Participants receive prescription glasses with violet excitation filter (420 nm wavelength, CR-39 material). Participants are instructed to wear glasses for 3 hours daily (11 AM to 2 PM) for 12 months to align with circadian rhythm.
- Single Vision LensesExisting treatment, for comparison
Participants receive standard single vision spectacle lenses (SVS index 1.56). Participants are instructed to wear glasses throughout all waking hours for 12 months.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Role of Advanced Technological Approaches for Myopia Control in Myopic Patients: A Randomized Controlled Trial of Lenslet Spectacles vs. Violet Excitation Filter Glasses vs. Single Vision Lenses
- Record updated
- 25 June 2026